Talk:Fluorouracil

Pharmacology High‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
High	This article has been rated as High-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Medicine C‑class Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
C	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Fluorouracil.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

FDA Warning on dangers to pets

Should this be added to the article? [1] 96.91.122.57 (talk) 20:08, 19 January 2017 (UTC)[reply]

Untitled

It DOES NOT INTERACT WITH DNA, but with thymidilate synthase.!!!!

Mode of administration ?

--Max Mayr 20:49, 5 October 2007 (UTC)[reply]

IV infusion or topical cream, depending of course on what it's being used for :) You may find this information in the Drugbox (blue table of data at the right of the page). Fvasconcellos (t·c) 03:57, 6 October 2007 (UTC)[reply]

Often used with Leucovorin? Huh. For Gastric. But not for Rectal, or Esophagus, or H/N, or any of the other sites that when added up outnumber Gastric a gazillion to one. 5FU is given without Leukovorin WAY more often than with it. Not even close. —Preceding unsigned comment added by 12.30.177.2 (talk) 00:19, 30 May 2008 (UTC)[reply]

You are probably right. If only I had a wp:verifiable reference, I would add this information to the article. --68.0.124.33 (talk) 01:18, 2 April 2009 (UTC)[reply]

WikiProject class rating

This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class. BetacommandBot 07:53, 10 November 2007 (UTC)[reply]

this drug is not give with leucovorin. you are thinking mtx <span style="font-size: smaller;" Leucovorin is given 24 hours after methotrexate to prevent some side effects, however it is often given concurrently with 5FU to enhance the drug's activity, <Polovich,M., Whitford, J.M., & Olsen,M. [Eds](2010)/ chemotherapy and biotherapy guidelines and recommendations for practice (3rd ed.) Pittsburgh, PA: Oncology Nursing Society.>--68.55.8.44 (talk) 09:43, 24 June 2010 (UTC) class="autosigned">—Preceding unsigned comment added by 68.157.18.100 (talk) 23:01, 3 May 2009 (UTC)[reply]

most common trade name?

Which brand or common name is most common? (for reference in a different article, want to give technical name and most common brand name)TCO (reviews needed) 15:28, 16 July 2011 (UTC)[reply]

And who came up with the silly brand name "Efudix"? Sounds like "Eff you, dicks!" Muzilon (talk) 08:55, 7 March 2015 (UTC)[reply]

Since when?

re: "has been used against cancer for about 40 years"

An old letter shows my grandma started taking this drug in mid July, 1964, and doesn't mention it being new or experimental. A quick search of FDA.gov shows it has been approved since at least April 25, 1962.(Drugs@FDA)

Orphaned references in Fluorouracil

I check pages listed in Category:Pages with incorrect ref formatting to try to fix reference errors. One of the things I do is look for content for orphaned references in wikilinked articles. I have found content for some of Fluorouracil's orphans, the problem is that I found more than one version. I can't determine which (if any) is correct for this article, so I am asking for a sentient editor to look it over and copy the correct ref content into this article.

Reference named "MD":

From Methotrexate: Brayfield, A, ed. (6 January 2014). "Methotrexate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 12 April 2014.
From Vincristine: Brayfield, A, ed. (13 December 2013). "Vincristine". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.
From Chemotherapy: Sweetman, S (ed.). Martindale: The Complete Drug Reference. London, UK: Pharmaceutical Press. Retrieved 8 February 2014.
From Tegafur: Sweetman, S, ed. (14 November 2011). "Martindale: The Complete Drug Reference". Pharmaceutical Press. Retrieved 12 February 2014.
From Omacetaxine mepesuccinate: Sweetman, S, ed. (14 November 2012). "Omacetaxine Mepesuccinate". Martindale: The Complete Drug Reference. Pharmaceutical Press. {{cite book}}: |access-date= requires |url= (help); |work= ignored (help)
From Doxorubicin: Brayfield, A, ed. (19 December 2013). "Doxorubicin". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 15 April 2014.

I apologize if any of the above are effectively identical; I am just a simple computer program, so I can't determine whether minor differences are significant or not. AnomieBOT ⚡ 07:15, 16 April 2014 (UTC)[reply]

Late effects?

Does 5-fu have any late-appearing effects, like one of the thrombocytopenia purpuras, for example? Thank you, Wordreader (talk) 03:04, 9 November 2014 (UTC)[reply]

DPD and contraindications

The "pharmacogenetics" section contains the sentence: "The FDA-approved drug label for fluorouracil states that the drug is contraindicated in patients with known DPD deficiency.[6]" This is not mentioned in the "contraindications" section; should this sentence or similar, or even the section, be added, or moved there (merged or as a subsection), or is it usual to keep it separate like this? Peter James (talk) 23:02, 23 October 2015 (UTC)[reply]

Assessment comment

The comment(s) below were originally left at Talk:Fluorouracil/Comments, and are posted here for posterity. Following several discussions in past years, these subpages are now deprecated. The comments may be irrelevant or outdated; if so, please feel free to remove this section.

Comment(s)

Press [show] to view →

While 5-FU and its active metabolite can be misincorporated into DNA and RNA, its primary mechanism of action is through inactivation of the enzyme Thymidylate Synthetase (TS). TS is responsible for synthesizing dTMP for the cell, using dUMP and 5,10-methylene tetrahydrofolate. Inactivation occurs due to covalent bonds formed between the active form of 5-FU (dFUMP), 5,10-MH4F, and the active site of TS. The concentration of dTMP in the cell is drastically reduced because of this, and DNA synthesis effectively halts, arresting the cell in S-phase. This can result in apoptosis in certain cells.

Because of the extremely low dTMP/dUMP ratio in these cells, misincorporation of dUMP and dFUMP in DNA and dFUMP in RNA certainly occurs, however this effect pales in comparison to the effect due to dTMP scarcity alone.

I would not consider myself an expert in 5-FU mechanisms of action, although I did a fair amount of research on the subject in college, but I am hesitant to update the main page until someone with more experience agrees with what I have said above, here.

Mike Ruane 07:46, 6 April 2007 (UTC)[reply]

Last edited at 07:46, 6 April 2007 (UTC). Substituted at 15:18, 29 April 2016 (UTC)

Other common side effects

1. Increased tinnitus. For me, that was quite strong, and I only had a low dose for a short time, following bowel cancer. And my audiologist told me that it is a common side effect with quite a few cancer chemotherapy drugs.

2. Lactose intolerance. My oncologist said that this was quite common for those who take this chemo following bowel cancer.

— Preceding unsigned comment added by 121.216.228.152 (talk) 10:44, 25 December 2016 (UTC)[reply]

Real costs.

Here in Australia, in 2015, a 3 week course (can't remember the mg) retailed at $700. Fortunately my health find paid for all of it. — Preceding unsigned comment added by 58.167.137.24 (talk) 05:40, 21 December 2018 (UTC)[reply]

Managing side effects

Problems with the following text:

"Use of a super-oxidized solution (SOS) can reduce the severity of the side effects and that many cannot continue treatment without the adjunct use of these solutions and/or hydrogels. The mechanism in which these SOS benefit the damage caused is through SOS ability to reduce Mast cell degranulation leading to reductions in inflammation, pain and prurutis in much the same way that SOS are used to manage dermatitis."

Primary source in tissue culture? We need to follow WP:MEDRS "Super-oxidized solution inhibits IgE-antigen-induced degranulation and cytokine release in mast cells". International Immunopharmacology. 7 (8): 1013–1024. 2007-08-01. doi:10.1016/j.intimp.2007.03.005. ISSN 1567-5769.

Ref does not mention "Fluorouracil"? Unless I am missing something.

Gold, Michael H.; Andriessen, Anneke; Dayan, Steven H.; Fabi, Sabrina G.; Lorenc, Z. Paul; Berg, Meagan-Helen Henderson (2017). "Hypochlorous acid gel technology—Its impact on postprocedure treatment and scar prevention". Journal of Cosmetic Dermatology. 16 (2): 162–167. doi:10.1111/jocd.12330. ISSN 1473-2165.

"The non-cytotoxic yet antimicoribal nature of SOS also prevents infection in the case of broken skin. The use of an SOS to mitigate side effects can be commenced immediately after treatment and continued safely until treatment is complete in much the same way these solutions and hydrogels are utilized to prevent and treat radiation dermatitis as a result of cancer radiothreapy treatments."

Which text from this ref supports the above content? Friedman, Adam; Cohen, Joel (2017). "Topical Approaches to improve surgical outcomes and wound healing: A review of efficacy and safety". Journal of Drugs and Dermatology. 16: 209–212 – via JDD Online.

Doc James (talk · contribs · email) 14:08, 9 January 2019 (UTC)[reply]